Related Experiment Video
Updated: May 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies
Julien Ablain1, Magdalena Leiva, Laurent Peres
1Université Paris Diderot, Sorbonne Paris Cité, France.
Abstract:
In PML/RARA-driven acute promyelocytic leukemia (APL), retinoic acid (RA) induces leukemia cell differentiation and transiently clears the disease. Molecularly, RA activates PML/RARA-dependent transcription and also initiates its proteasome-mediated degradation. In contrast, arsenic, the other potent anti-APL therapy, only induces PML/RARA degradation by specifically targeting its PML moiety. The respective contributions of RA-triggered transcriptional activation and proteolysis to clinical response remain disputed. Here, we identify synthetic retinoids that potently activate RARA- or PML/RARA-dependent transcription, but fail to down-regulate RARA or PML/RARA protein levels. Similar to RA, these uncoupled retinoids elicit terminal differentiation, but unexpectedly fail to impair leukemia-initiating activity of PML/RARA-transformed cells ex vivo or in vivo. Accordingly, the survival benefit conferred by uncoupled retinoids in APL mice is dramatically lower than the one provided by RA. Differentiated APL blasts sorted from uncoupled retinoid-treated mice retain PML/RARA expression and reinitiate APL in secondary transplants. Thus, differentiation is insufficient for APL eradication, whereas PML/RARA loss is essential. These observations unify the modes of action of RA and arsenic and shed light on the potency of their combination in mice or patients.
Insights
Retinoic acid (RA) and arsenic treat acute promyelocytic leukemia (APL) by degrading PML/RARA. New synthetic retinoids cause differentiation but not PML/RARA loss, proving degradation is essential for APL eradication.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Acute promyelocytic leukemia (APL) is driven by PML/RARA.
- Retinoic acid (RA) and arsenic are effective APL therapies.
- The mechanism of RA's efficacy, particularly the roles of transcriptional activation versus protein degradation, is debated.
Purpose of the Study:
- To investigate the distinct contributions of PML/RARA transcriptional activation and degradation in APL treatment.
- To determine if differentiation alone is sufficient for APL eradication.
- To unify the understanding of RA and arsenic mechanisms in APL.
Main Methods:
- Synthesized novel retinoids that selectively activate RARA/PML-RARA transcription without inducing protein degradation.
- Assessed the effects of these synthetic retinoids on APL cell differentiation, leukemia-initiating activity, and survival in mouse models.
- Analyzed PML/RARA protein levels in differentiated APL cells from treated mice.
Main Results:
- Synthetic retinoids induced terminal differentiation of APL cells, similar to RA.
- These 'uncoupled' retinoids failed to degrade PML/RARA protein.
- APL cells treated with uncoupled retinoids retained leukemia-initiating capacity, and mice showed limited survival benefit compared to RA treatment.
- Differentiated APL cells from uncoupled retinoid-treated mice still expressed PML/RARA and could reinitiate leukemia.
Conclusions:
- PML/RARA protein degradation, not just differentiation, is essential for eradicating APL.
- This finding clarifies the distinct roles of transcriptional activation and proteolysis in RA and arsenic therapies.
- Understanding these mechanisms highlights the importance of PML/RARA loss for effective APL treatment and combination therapies.
Related Concept Videos
Co-activators and Co-repressors
Regulation of Expression at Multiple Steps
Abnormal Proliferation
RNA Polymerase II Accessory Proteins
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...

